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Summary. The effects of barbiturates on the GABA·re-
ceptor complex and the A1 adenosine receptor were studied. 
At the GABA-receptor complex the barbiturates inhibit-
ed the binding of [35S]t-butylbicyclophosphorothionate Ce 5S]TBPT) and enhanced the binding of eHJdiazepam. 
Kinetic and saturation experiments showed that both effects 
were allosteric. Whereas all barbiturates caused complete 
inhibition of [35S]TBPT binding, they showed varying de-
grees of maximal enhancement of [3H]diazepam binding; 
(±)methohexital was idenafied as the most efficacious com-
pound for this enhancement. At the A 1 adenosine receptor 
all barbiturates inhibited the binding of [3H]N6-phenyl-
isopropyladenosine ([3H]PIA) in a competitive manner. The 
comparison of the effects Oll eH]diazepam and [3H]PIA 
binding showed that excitatory barbiturates interact prefer-
entially with the A1 adenosine receptor, and sedative/ 
anaesthetic barbiturates with the GABA-receptor complex. 
It is speculated that the interaction with these two receptors 
might be the basis of the excitatory versus sedative/ 
anaesthetic properties of barbiturates. 
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Introduction 
Barbiturates are widely used as anaesthetic, sedative and 
anticonvulsant drugs. They have three distinct properties 
which can - to a varying extent - be found in any member 
of this group: these are the sedative/anaesthetic, the anti-
convulsant and the excitatory effects (Nico111978). 
Several theories have been put forward to explain the 
mechanism of their CNS-depressant actions. These theories 
can be subdivided into those which favour a relatively non-
specific effect such as perturbation of membrane Iipids 
(Seeman 1972), and those that assume a more specific in-
teraction with membrane proteins, in particular with 
hormone or neurotransmitter receptors (LaBella 1981). A 
large body of evidence has been accumulated that the 
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sedativejanaesthetic effects of barbiturates might be caused 
by such a specific interaction with the GABA-receptor-
complex, which has been reviewed by Olsen (1982). This 
complex appears to contain a chloride channel as weil 
as binding sites for GABA, benzodiazepines and convulsants 
like picrotoxinin (Olsen 1982). A go·od correlation between 
the, effects of barbiturates on radioligand binding to the 
GABA receptor-complex, the enhancement of chloride 
effiux and the anaesthetic potency suggests that this is the 
site of the sedative and anaesthetic effects of barbiturates 
(Schwartz et al. 1985). The low efficacy of phenobarbital at 
this receptor, however, indicates that the GABA-receptor 
complex does not mediate the anticonvulsant effect of bar-
biturates (Schwartz et al. 1985; Leeb-Lundberg and Olsen 
1982); this supports the early concept of distinct sedative/ 
anaesthetic and anticonvulsant properties of barbiturates 
(see Harvey 1985). 
In addition to these inhibitory effects on the central 
nervous system, barbituratesalso possess excitatory proper-
ties. These can be seen with almost any barbiturate, but are 
moreprominent with certain derivatives (Nicoll1978). From 
a study on the effects of several inhibitory and excitatory 
barbiturates, Downes et al. (1970) concluded, that these two 
effects must be mediated by different mechanisms. Similar 
conclusions have been drawn from sturlies showing that 
several excitatory barbiturates interact with the GABA-re-
ceptor complex in a similar manner as do inhibitory barbitu-
rates (Leeb-Lundberg and Olsen 1982). However, the mech-
anism responsible for the excitatory effects has so far not 
been identified. 
Recently we have reported that barbiturates interact with 
A 1 adenosine receptors in the range of pharmacologically 
relevant concentrations (Lohse et al. 1984a). A1 adenosine 
receptors mediate a variety ofbiological effects of adenosine. 
In the central nervaus system they are responsible for the 
inhibitory effects of adenosine such as the reduction of 
neuronal firing, the inhibition of neurotransmitter release, 
and - in intact animals - sedative and anticonvulsant 
effects (Dunwiddie 1985). Barbiturates act as competitive 
antagonists at the A1 receptor (Lohse et al. 1985). Therefore 
it is tempting to speculate that the excitatory effects of bar-
biturates are mediated by A 1 receptors, whereas the inhibi-
tory effects are mediatedvia the GABA-receptor complex. 
In order to test this hypothesis we undertook the present 
study to determine the affinities and efficacies of a series of 
barbiturates at the GABA-receptor complex and the A 1 
receptor and compare these effects with their pharmacologi-
cal properties. 
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Experimental procedures 
Materials 
[35S]TBPT (90.2 Ci/mmol), unlabelled TBPT, [3H]diazepam 
(70.0 Cijmmol) and [3H]PIA (49.9 Ci/mmol) were obtained 
from New England Nuclear, Dreieich, FRG. The Stereo-
isomers of N-methyl-5-(1-cyclohexen-1-yl)-5-ethylbarbitu-
ric acid (MCB), N-methyl-5-phenyl-5-propylbarbituric acid 
(MPPB), hexobarbital and mephobarbital were kind gifts of 
Prof. Knabe, Saarbrücken, FRG, and the Stereoisomers of 
pentobarbital were kindly provided by Prof. Camey, 
Oklahoma. All other materials were from sources previously 
described (Lohse et al. 1984 a, 1985). 
Methods 
Preparation of rat brain membranes. Membranes from rat 
forebrains were prepared by a method adapted from Squires 
et al. (1983), using the centrifugation steps described earlier 
(Lohse et al. 1985). In brief, whole forebrains from male 
Wistar rats were placed in 0.32 M sucrose at 0° C; the tissue 
was homogenized with a glassjteflon homogenizer at 
500 rpm for 30 s. The homogenate was centrifuged at 
1,000 x g for 10 min and the resulting supernatant again 
centrifuged at 100,000 x g for 30 min. The ·pellet was re-
suspended in 1 mM EDTA/Tris, pH 7.4, and dialyzed four 
times against 50 vol. of double-distilled waterat 4° C for 2 h 
each. After the dialysis the membranes were pelleted by 
centrifugation at 100,000 x g for 30 min, and the pellets were 
resuspended in the buffers used for the respective experi-
ments (see below) at a protein concentration of 5-10 mg( 
ml. The protein concentration was determined by a mo-
dification of the Lowry method as described by Peterson 
(1977). 
Radioligand binding assays. All radioligand binding experi-
ments were done under conditions reported to be optimal for 
the individual binding assay. The radioligand concentration 
was always below the K0 -value of the radioligand. 
The binding of [35S]TBPT, a convulsant that binds to 
and acts via the picrotoxinin-binding site of the GABA-re-
ceptor complex, to rat brain membranes was measured with 
some modifications as described by Squires et al. (1983). 
The membranes (100-150 Jlg protein) were incubated with 
the radioligand in 250 Jll of 50 mM Tris/HCl, pH 7.5, con-
taining 200 mM KBr. Unless indicated otherwise the 
radioligand concentration was 1 nM. The higher concentra-
tion of buffer compared to the 5 mM used by Squires et 
al. (1983) was necessary to maintain a constant pH in the 
presence of barbiturates. For equilibrium binding experi-
ments the incubation at 25°C Jasted for 2 h and was 
terminated by filtration through Whatman GF/B glass-fibre 
filters. Nonspecific bindingwas defined by the presence of 
100 J.LM picrotoxin and amounted to about 15% ofthe total 
binding at 1 nM [35S]TBPT. 
The binding of [3H]diazepam to the benzodiazepine-
binding site of the GABA-receptor complex was measured 
at ooc as described by Leeb-Lundberg and Olsen (1982) 
using 50 mM sodium phosphate buffer, pH 7.0, containing 
200 mM NaCl. The radioligand concentration was 0.5 nM. 
The binding of the A 1 adenosine receptor agonist 
[ 3H]PIA (1 nM) to rat brain membranes was measured at 
25°C as described earlier (Lohse et al. 1985). 50 mM Tris/ 
HCl, pH 7.4, was used as the incubation buffer. Endogenaus 
adenosine was removed by the addition of 0.2 U /ml adeno-
sine deaminase. 
Adenylate cyc/ase assays. The activity of adenylate cyclase 
of rat brain membranes was determined as described (Lohse 
etal.1985). 
Data analysis. Equilibrium binding data were analyzed by 
non-linear curve-fitting with the program SCTFIT (De Lean 
et al. 1982) providing parameter estimates for binding to 
multiple sites. Kinetic binding data were fitted by non-linear 
regression to mono- or multiexponential equations (Lohse 
et al. 1984b). 
Other concentration-response curves were analyzed by 
non-linear curve-fitting to the Hill-equation as described 
(Lohse et al. 1986). The EC50-values of such curves denote 
the ligand concentration leading to the half-maximal effect 
of the individual curves. In the case of the enhancement 
of [3H]diazepam binding, EC15%-values indicate the Iigand 
concentration causing an enhancement by 15% ofthe basal 
value. 
All data are from at least three independent experiments 
with duplicate samples, and are given as means ±SEMs or 
with 95% confidence limits. 
Results 
[35S]TBPT bound in a saturable manner to dialyzed brain 
membranes, with a K0 -value of 33 nM (30- 36 nM) and 
a binding capacity Bmax of 690 ±55 fmoljmg protein. The 
GABA-agonist muscimol inhibited the binding with an 
ICso-value of 73 nM, whereas the GABA-antagonist bi-
cuculline was without any effect in concentrations up to 
10 J!M; this indicates an intact GABA-ergic modulation of 
the binding of [35S]TBPT and the essentially complete re-
moval of endogenous GABA from the membrane prepara-
tion (Squires et al. 1983). · 
The specific binding of [35S]TBPT was inhibited in a 
concentration-dependent manner by all barbiturates tested 
with the exception of barbituric acid itself. Figure 1 shows 
the inhibition curves obtained with the sedativejanaesthetic 
barbiturates (±)methohexital and (±)pentobarbital and the 
anticonvulsant phenobarbital. All three inhibited the bind-
ing of [35S]TBPT with Hili coefficients of 1. The three bar-
biturates (as weil as all other barbiturates tested) caused 
complete inhibition of P5S]TBPT binding at higher concen-
trations, but the affinities were markedly different. 
It has been suggested that the enhancement of 
[ 3H]diazepam binding by barbiturates can be used to 
estimate not only their affinity, but also their efficacy at the 
GABA-receptor complex (Leeb-Lundberg and Olsen 1982). 
Figure 2 .shows that the three barbiturates, which led to the 
same full inhibition of[35S]TBPT binding, had very different 
efficacies in enhancing [3H]diazepam binding. (±)Me-
thohexital caused an enhancement by almost 1 SO%, 
and pentobarbital by more than 100°/o, whereas phe-
nobarbital had no effect. Such differences have led to the 
concept of full and partial agonist properties of barbiturates 
(Leeb-Lundberg and Olsen 1982). However, the order of 
potency of the three barbiturateswas the same in the two 
experiments. 
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Fig. 1. Inhibition of [3 5SJTBPT binding by barbiturates. The binding 
of [35S]TBPT to rat brain membranes was measured as described 
under Methods in the presence of various concentrations of 
(±)methohexital (e), (±)pentobarbital (•), and phenobarbital ( + ). The control value was 18.7 ± 1.4 fmol/mg protein. Data repre-
senting the means of 3 experiments were fitted to the Hili equation 
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Fig. 2. Effects of barbiturates on the binding of [3H]diazepam. The 
binding of [3 H]diazepam to rat brain membranes was measured as 
described under Methods in the presence of various concentrations 
of (±)methohexital (e), (±)pentobarbital (•), and phenobarbital ( + ). The control value was 93.5 ± 4.7 fmol/mg protein. Data repre-
senting the means of 3 experiments were fitted to the Hill equation 
In accordance with earlier reports (Leeb-Lundberg et al. 
1980; Skolnick et al. 1981), we found that the enhancement 
of [3HJdiazepam binding by barbiturates was due to an 
increase in affinity without alterations in the binding ca-
pacity (data not shown). Both competitive and non-competi-
tive mechanisms have been reported for the inhibition of 
(35S)TBPT binding by barbiturates (Ramanjaneyulu and 
Ticku 1984; Trifiletti et al. 1985). We studied this question 
in kinetic and equilibrium saturation experiments. 
The dissociation kinetics of [35S]TBPT bindingwas the 
same whether initiated by a saturating concentration of 
unlabelled Iigand or of picrotoxin (Fig. 3). However, the 
dissociation following the addition of a high concentration 
of a barbituratewas extremely rapid and almost complete 
within 15 s. This was observed with either the barbiturate 
alone or the barbiturate together with a high concentration 
of unlabelled TBPT or of picrotoxin. The dissociation 
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Fig. 3. Dissociation kinetics of [35S]TBPT binding. After achieve-
ment of equilibrium of e 5S]TBPT binding to rat brain membranes, 
the dissociation of the radioligand was initiated by the addition of 
1 J.1M unlabelled TBPT ( + ), 100 J.LM picrotoxin (•). or 1 mM 
(±)methohexital ( e ). The data representing means of 3 experiments 
were fitted to a monoexponential equation giving the following 
dissociation constants: k_ 1 0.017min- 1 (TBPT), k_ 1 0.018min- 1 (picrotoxin). No fit could be obtained for methohexital 
(k - 1 > 10 min- 1 ). The use of multiphasic equations did not Iead to 
a significant improvement of the fits 
Table 1. Effects of methohexital on equilibrium binding of 
[35S]TBPT. The Saturation of [35S]TBPT binding (1-100 nM) to 
rat brain membranes was measured under control conditions and 
in the presence of 30 J.1M (±)methohexital. The data were analyzed 
by nonlinear curve-fitting. In both cases, only one component was 
detected, as also indicated by a linear Scatchard plot. Values rep-
resent means ± SEMs or 95% confidence intervals of 3 experiments 
Control 
(±)Methohexital (30 J.LM) 
Bnuu Ko 
(fmol/mg (nM) 
protein) 
514 ±51 
85±22 
29.8 (26.1 - 34.0) 
26.2 (19.7 -34.9) 
kinetics suggest that the barbiturate does not act at the same 
site as TBPT or picrotoxin. Saturation experiments in the 
absence and presence of 30 J.I.M methohexital confirmed 
the hypothesis of a non-competitive inhibition (Table 1): 
Methohexital caused a marked reduction of the binding 
capacity without affecting the affinity ofthe remaining bind-
ing sites. 
Table 2 summarizes the affinity and efficacy of a series of 
barbiturates at the GABA-receptor complex as detennined 
from the inhibition of [35S]TBPT binding and the enhance-
ment of [3H]diazepam binding. On the whole, the order of 
potency determined by the two methods agrees relatively 
weil, although the EC50-values of the enhancement of 
[3H]diazepam binding are generally higher. For several bar-
biturates there is a marked stereoselectivity. The efficacy of 
the barbiturates ranged from 0 to almost 150% enhancement 
of [3H]diazepam binding. 
The ECso-values of the individual curves do not allow a 
comparison between the barbiturates, as they do not take 
into account the markedly different maximal effects. In such 
cases, the calculation of the Iigand concentration causing a 
constant absolute enhancement can be used. We chose for 
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Table 2. Effects of barbiturates on [35S]TBPT and [3H]diazepam binding. Eman denotes the maximal enhancement above basal value in %. 
The ba~al ~alue was 94 ± 5 fmolfmg protein. Values are means ±SEMs or 95% confidence intervals of 3 to 5 experiments with triplicate 
detemunattons 
Barbiturate [35S]TBPT 
ICso (J.LM) 
(±)Methohexital 12 (8- 20) 
(±)Thiopental 21 (12- 37) 
(±)Pentobarbital 63 (54- 73) 
(±)Seco barbital 81 (69- 97) 
(±)Hexobarbital 130 (103- 170) 
Amobarbital 140 (132- 152) 
Phenobarbital 360 {275- 463) 
Stereoisomers 
(-)DMBB 21 (14- 34) 
(+)DMBB 55 (40- 75) 
(- )Pentobarbital 60 (39- 91) 
( + )Pentobarbital 95 (58- 156) 
(- )Mephobarbital 35 (25- 50) 
( + )Mephobarbital 465 (374- 578) 
(-)MPPB 67 (30- 146) 
(+)MPPB 720 (373-1,394) 
(-)MCB 80 (40- 165) 
(+)MCB 365 (193- 690) 
( + )Hexobarbital 110 (58- 194) 
(- )Hexobarbital 340 (228- 507) 
this purpese an enhancement by 15%, representing the half-
maximal effect of (- )MPPB, which is of the sedative/ 
anaesthetic barbiturates the one causing the least enhance-
n;J.ent of[3H]diazepam binding. These EC15%-values are used 
for the comparison with the effects of barbiturates at A 1 
adenosine receptors. 
Wehave previously shown that barbiturates are competi-
tive antagonists at A1 adenosine receptors (Lohse et al. 
1985). None of the barbiturates used in this study had any 
agonist activity at A1 receptors, as evidenced by a Iack of 
adenylate cyclase inhibition in both rat brain and fat cell 
membranes (data not shown). The affinity of the barbitu-
rates for the A1 receptor was tested in competition experi-
ments for the binding of [3H]PIA to rat brain membranes. 
Because of their full antagonist properties, their affinities 
determined in the competition experiments were used for a 
comparison with their effects at the GABA-receptor 
complex. 
The effects of the barbiturates on the A1 receptor and 
the GABA-receptor complex are compared in Table 3. The 
selectivity for the GABA-receptor complex was calculated 
by dividing the K1-values by the respective EC15%-values. 
Table 3 also gives data from the Iiterature on the pharmaco-
logical properties (sedativefanaesthetic vs. excitatory) ofthe 
individual compounds, as observed in studies with intact 
animals (see references in Table 3). 
The top group lists barbiturates which are used in clinical 
practice as sedatives/anaesthetics. Allthese compounds have 
a preferential action at the GABA-receptor complex, as 
indicated by a "GABA-selectivity" factor above 1. In 
contrast, phenobarbital, which is used because of its anti-
convulsant properties, does not cause a measurable enhance-
ment [3H]diazepam binding. 
[3H]Diazepam 
ECso (J.LM) Emax (%) 
69 (62- 78) 144± 4 
111 (105- 118) 99± 7 
302 (241- 379) 111 ± 8 
147 (120- 180) 104± 3 
277 (155- 495) 41 ± 8 
419 (269- 652) 91 ± 8 
0 
35 (32- 39) 82± 6 
108 (67- 174) 49± 9 
232 (179- 300) 121 ± 10 
271 (184- 397) 71 ± 16 
103 (87- 120) 46± 5 
0 
195 {139- 273) 31 ± 6 
0 
493 (311- 782) 92± 8 
705 (406-1,224) 43± 9 
339 (231- 497) 41 ± 10 
1,434 (1 ,297-1 ,585) 47 ± 13 
The second group comprises the Stereoisomers of 
pentobarbital and hexobarbital, which all have sedative/ 
anaesthetic properties. In both pairs the more potent 
anaesthetic isomer (Wahlström 1966; Büch et al. 1969) had 
both a lower EC 15 % in enhancing [3H]diazepam binding 
and a somewhat higher selectivity for the GABA-receptor 
complex. 
Thirdly, we investigated a nurober of stereoisomers, 
which produce opposite pharmacological effects. In each of 
these pairs, the sedativefanaesthetic isomer had a preferen-
tial action at the GABA-receptor complex, whereas the ex-
citatory isomer had a higher affinity for the A1 receptor. 
Two of these excitatory isomers had no measurable effect 
on the binding of [3H]diazepam, although at high concentra-
tions they inhibited [35S]TBPT binding. 
Discussion 
The understanding of the molecular mechanisms of barbitu-
rate effects is still very incomplete. A Iot of pharmacological 
evidence suggests that the three major effects - sedative/ 
anaesthetic, anticonvulsant and excitatory - are mediated 
by different mechanisms (Leeb-Lundberg and Olsen 1982; 
Harvey 1985; Downes et al.1970). Although several authors 
assume that relatively non-specific interactions of barbitu-
rates with the plasma membrane form the basis of the 
depressant effects (Seeman 1972), this theory cannot account 
for the marked differences of several pairs of stereoisomers. 
In fact, these differences suggest more specific interactions 
in particular with membrane-bound receptors (Andrews and 
Mark 1982). 
Table 3. Affinities of barbiturates for A1 adenosine receptors and 
GABA-receptor complexes 
Barbiturate A1 GABA GABA- Pharma-
receptor receptor selec- cological 
[ 3H]PIA [ 3H]dia- tivity effecta 
Ki (~M) zepam K1 (At)/ S;E; 
EClS% EClS% AC 
(J.LM) (GABA) 
(±)Methohexital 340 9 38 s 
(±)Thiopental 170 41 4.2 s 
(±)Secobarbital 120 42 2.9 s 
(±)Hexobarbital 620 210 2.9 s 
(±)Pento barbital 110 70 1.6 s 
Amobarbital 150 110 1.4 s 
Phenobarbital 360 oob 0 AC 
Stereoisomers with similar pharmacology 
(- )Pentobarbital 91 37 2.5 s 
( + )Pentobarbital 230 115 2.0 s 
( + )Hexobarbital 520 250 2.1 s 
(- )Hexobarbital 720 500 1.5 s 
Stereoisomers with different pharmaco/ogy 
(-)MCB 1 070 105 10 s 
(+)MCB 310 410 0.7 E 
(- )Mephobarbital 580 67 8.4 s 
( + )Mephobarbital 350 00 0 E 
(-)DMBB 26 13 2.0 s 
(+)DMBB 60 80 0.7 E 
(-)MPPB 260 200 1.3 s 
(+)MPPB 520 00 0 E 
a The barbiturates are classified as either sedativejanaesthetic (S), 
excitatory (E), or anticonvulsive (AC) according to the following 
reports: Harvey (1985); Downes et al. (1970); Wahlström (1966); 
Wahlström and Norberg (1984): Büch et al. (1968, 1969, 1970, 1973) 
b oo indicates that the compound does not enhance [3H]diazepam 
binding 
We have investigated the effects of barbiturates on two 
such receptors, the GABA-receptor complex and the A1 
adenosine receptor. At the GABA-receptor complex, bar-
biturates inhibited the binding of[35S]TBPT, as reported by 
others (Squires et al. 1983; Ramanjaneyulu and Ticku 1984; 
Trifiletti et al. 1985). In contrast to the reports by 
Ramanjaneyulu and Ticku (1984) and Trifiletti et al. (1985) 
we observed no effect of methohexital on the K0 -value of 
[35S]TBPT, resulting in a truly non-competitive inhibition. 
Together with the markedly different dissociation kinetics 
following methohexital on the one side, and picrotoxin or 
unlabelled TBPT on the other side, this suggests that bar-
biturates act via a site distinct from the TBPT-binding site. 
The inhibition of [35S]TBPT binding seems to occur via an 
allosteric mechanism. 
The enhancement of [3H]diazepam binding by barbitu-
rates occurred also via an allosteric mechanism (Leeb-
Lundberg and Olsen 1982; Skolnick et al. 1981). However, 
although all barbiturates were equally effective in inhibiting 
the binding of [35S]TBPT, they had very different efficacies 
in enhancing the binding of [3H]diazepam. The highest 
efficacy had methohexital, which caused significantly greater 
enhancement than the previously identified most effective 
compounds pentobarbital and secobarbital (Leeb-Lundberg 
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and Olsen 1982). Therefore, with respect to methohexital all 
other barbiturates must be regarded as partial agonists with 
varying efficacies. Some ofthem, for example phenobarbital, 
produced no measurable enhancement of [3H]diazepam 
binding at all. However, this may be due to the fact that 
high concentrations ( > 10 mM) of most barbiturates inhibit 
the binding of [3H]diazepam, which is most likely due to an 
alkalinisation of the incubation buffer by high concentra-
tions of barbiturates. Such effects may obscure a minor 
enhancement of [3H]diazepam binding, so that we cannot 
exclude a very low intrinsic activity of those barbiturates 
which produced no measurable enhancement. 
I t has been suggested that the enhancement of 
[3H]diazepam binding is related to the sedativejanaesthetic 
effects of barbiturates (Leeb-Lundberg and Olsen 1982), 
which is supported by a correlation of this effect both with 
an enhancement of chloride-fluxes and anesthetic potency 
(Schwartz et al. 1985; Leeb-Lundberg et al. 1980). Whereas 
those barbiturates which produced no measurable enhance-
ment of [3H]diazepam binding have only little or no sedative 
properties, some of the known sedativejanaesthetic barbitu-
rates, for example (±)hexobarbital, produce only a small 
maximal enhancement of [3H]diazepam binding. Therefore 
we chose the EC15%-values as the basis for the comparison 
of different barbiturates as detailed in the results section. 
This would suggest that a minor enhancement of 
[3H]diazepam binding corresponds already to anaesthesia. 
This view is supported by the fact that the EC15 %-values of 
several barbiturates agree weil with the free plasma concen-
trations found during anaesthesia; for example, during 
anaesthesia in the rat the free plasma concentration of 
(±)pentobarbital (EC15% 70 1J.M) has been estimated at 
80 IJ.M (Lohse et al. 1985; Büch et al. 1969), of (- )MCB 
(EC15 % 105 IJ.M) at 80-180 IJ.M (Büch et al. 1970), and of 
(- )mephobarbital (EC15 % 67 IJ.M) at 60-200 IJ.M (Büch et 
al. 1968). Likewise, during anaesthesia in man, plasma levels 
of methohexital (EC15 % 9 J.!M) are in the range of 10 J!M 
(Breimer 1976), and of thiopental (EC15 % 46 JJ.M) in the 
range of 16-651J.M (Burch and Stanski 1983). Moreover, 
the EC15 %-values ofthe enhancement of[3H]diazepam bind-
ing also agree relatively weil with the IC50-values of the 
inhibition of [35S]TBPT binding. 
Whereas at the GABA-receptor complex only allosteric 
effects of barbiturates have been demonstrated, we· have 
previously shown that at the A1 adenosine receptor barbitu-
·rates interact with the binding site in a competitive manner 
(Lohse et al. 1985). In agreement with earlier results, all 
barbiturates appeared to be antagonists at this receptor. · 
This is a property which they share with theophylline and 
caffeine, which are known for their stimulatory effects on 
the central nervous system. Therefore it was tempting to 
speculate that blockade of A1 adenosine receptors by bar-
biturates might be the basis of their excitatory actions. Re-
cently we have shown that barbiturates can enhance the 
release of neurotransmitters in the hippocampus by blocking 
presynaptic A1 receptors (Lohse et al. 1987). This could be 
related to their excitatory actions. The resulting speculation 
would be that excitatory barbiturates preferentially block 
the A1 receptor, whereas sedativejanaesthetic barbiturates 
preferentially act at the GABA-receptor complex. 
The investigation of the effects of barbiturates at either 
receptor alone has not led to a possible explanation of their 
different pharmacological actions. Thus, it was noted that 
several excitatory barbiturates also had agonist properties 
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at the GABA-receptor complex as seeninan enhancement 
of [3H]diazepam binding (Leeb-Lundberg and Olsen 1982). 
We observed such an enhancement for (+)DMBB and 
( + )MCB, but not for other excitatory isomers. This suggests 
that these compounds possess sedative/anaesthetic proper-
ties. On the other hand, whereas in several pairs of 
stereoisomers the excitatory isomer was more potent at the 
A1 receptor than its sedativejanaesthetic counterpart, this 
was not the case with all of these pairs (Lohse et al. 1985). 
However, when the effects on both receptor systems 
are taken together, we obtain data which are compatible 
with this hypothesis. In particular, the investigation of 
stereoisomers with opposite pharmacological effects lends 
support to this idea. In each of these pairs, the excitatory 
property correlated with a preferential action at the A1 
receptor, as indicated by "GABA-selectivity" factors below 
1. In contrast, sedativejanaesthetic barbiturates had 
"GABA-selectivity" factors above 1. A particularly high 
selectivity for the GABA-receptor complex was calculated 
for methohexital, followed by thiopental, which agrees well 
with their usefulness in the induction of anaesthesia. 
The anticonvulsalit barbiturate phenobarbital had 
practically no activity at the GABA-receptor complex 
neither in our experiments nor in several other studies (Leeb-
Lundberg et al. 1980; Schwartz et al. 1985; seealso Harvey 
1985). This agrees with the view mentioned in the introduc-
tion that the anticonvulsant effects of barbiturates are not 
mediated via the GABA-receptor complex. Possible reasons 
why minor effects of phenobarbital on [3H]diazepam bind-
ing - which would correspond to its minor sedative 
effects - were not observed under our experimental 
conditions have been discussed above. However, it is inter-
esting to note that the so-called paradoxical excitement is 
most frequently seen with phenobarbital (Harvey 1985). 
This might be related to the observation that - although 
therapeutic Ievels of phenobarbital (40-100 J.LM, Harvey 
1985) are below its Ki-value at the A1 receptor -
phenobarbital has a GABA-selectivity factor of 0. 
Obviously, our data do not exclude the possibility that 
other factors contribute to either the excitatory or the 
sedativejanaesthetic effects ofbarbiturates. In addition, they 
provide no clues on the mechanism of anticonvulsant action, 
as clearly seen with phenobarbital. However, they may pro-
vide a useful speculation on the mechanisms ofthe excitatory 
and sedativejanaesthetic actions. They also show that 
the simultaneous investigation of different biochemical 
mechanisms may be necessary to understand a phannaco-
logical effect. 
It remains tobe seen, how the inputs from the GABA-
receptor complex and the A 1 adenosirre receptor could be 
integrated to produce an overall effect, which may be either 
excitatory or sedativefanaesthetic. 
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